lomitapide mesylate - Profile

What are the generic drug sources for lomitapide mesylate and what is the scope of patent protection?

Lomitapide mesylate is the generic ingredient in one branded drug marketed by Chiesi and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lomitapide mesylate has thirty-six patent family members in twenty-one countries.

Summary for lomitapide mesylate

International Patents:	36
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lomitapide mesylate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lomitapide mesylate

Constraining patent/regulatory exclusivity:

7,932,268

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for lomitapide mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-007	Feb 25, 2026		RX	Yes	No	12,472,172
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-007	Feb 25, 2026		RX	Yes	No	7,932,268
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012		RX	Yes	No	7,932,268
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012		RX	Yes	No	12,472,172
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012		RX	Yes	No	7,932,268
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012		RX	Yes	No	12,472,172
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012		RX	Yes	No	7,932,268

Expired US Patents for lomitapide mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012	5,739,135
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012	9,364,470
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012	10,555,938
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-005	Apr 23, 2015	5,712,279
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-004	Apr 23, 2015	6,492,365
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012	10,016,404
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012	5,712,279

International Patents for lomitapide mesylate

Country	Patent Number	Title	Estimated Expiration
Japan	2023536855
New Zealand	549721	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
South Korea	20060129082	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS
Montenegro	02070	POSTUPCI ZA LEČENJE POREMEĆAJA ILI BOLESTI POVEZANIH SA HIPERLIPIDEMIJOM I HIPERHOLESTEROLEMIJOM UZ MINIMIZACIJU SPOREDNIH EFEKATA (METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS)
Japan	5902760
European Patent Office	4188372
European Patent Office	1725234	TRAITEMENT A FAIBLES EFFETS SECONDAIRES CONTRE DES AFFECTIONS LIEES A L'HYPERLIPIDEMIE ET L'HYPERCHOLESTEROLEMIE (METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS)

Supplementary Protection Certificates for lomitapide mesylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725234	1490006-2	Sweden		PRODUCT NAME: LOMITAPID OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/13/851/001 20130731
1725234	C 2014 003	Romania		PRODUCT NAME: LOMITAPIDA SAU O SARE ACCEPTABILA FARMACEUTIC SAU PIPERIDIN-N-OXIDUL ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/851/001-003; DATE OF NATIONAL AUTHORISATION: 20130731; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/851/001-003; DATE OF FIRST AUTHORISATION IN EEA: 20130731
1725234	14C0003	France		PRODUCT NAME: LOMITAPIDE , OU UN SEL PHARMACEUTIQUEMENT ACTIF DE CELUI-CI.; REGISTRATION NO/DATE: EU/1/13/851/001 20130805
1725234	132014902228079	Italy		PRODUCT NAME: LOMITAPIDE E OGNI SUA FORMA TERAPEUTICAMENTE EQUIVALENTE COME PROTETTA DAL BREVETTO BASE(LOJUXTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/851/001/-003, 20130805
1725234	2014C/002	Belgium		PRODUCT NAME: LOMITAPIDE ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE TELLE QUE PROTEGEE PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/13/851/001 20130805
1725234	2/2014	Austria		PRODUCT NAME: LOMITAPID BZW. DESSEN PHARMAZEUTISCH ANNEHMBARE SALZE; REGISTRATION NO/DATE: EU/1/13/851/001-EU/1/13/851/003 20130731
1725234	CR 2014 00002	Denmark		PRODUCT NAME: LOMITAPID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER PIPERIDIN N-OXIDET DERAF, HERUNDER LOMITAPIDMESYLAT; REG. NO/DATE: EU/1/13/851/001-003 20130805

Investment Scenario, Market Dynamics, and Financial Trajectory for Lomitapide Mesylate

Last updated: February 3, 2026

Executive Summary

Lomitapide mesylate, marketed as Juxtapid (USA) and Lojuxta (Europe), is a lipid-lowering agent approved mainly for homozygous familial hypercholesterolemia (HoFH). Given its niche application, high development and marketing costs, and competitive landscape, its market remains specialized. As of 2023, the global market for lomitapide is characterized by steady growth prospects influenced by increasing awareness of rare lipid disorders, regulatory support for orphan drugs, and ongoing pipeline developments. Investment considerations hinge on the drug’s regulatory exclusivity, reimbursement landscape, manufacturing costs, and emerging biosimilar or generic challenges.

This analysis provides a comprehensive overview of lomitapide's investment potential, market forces, and financial trajectory, serving stakeholders interested in biotech/pharmaceutical investments, strategic alliances, or competing product development.

---

1. Market Overview and Therapeutic Profile

1.1. Therapeutic Indication and Mechanism of Action

Aspect	Details
Approved Indication	Homozygous familial hypercholesterolemia (HoFH)
Regulatory Status	FDA (2012), EMA (2013) approval; orphan drug designation for HoFH
Mechanism	Mipomersen-like action: MTP (microsomal triglyceride transfer protein) inhibitor reducing VLDL and LDL levels

1.2. Market Size and Epidemiology

Parameters	Data
Global HoFH Estimated Population	~1 in 1 million, or approximately 10,000–20,000 globally (most in Western countries)
Addressable Market in 2023 (USD)	Estimated at $150–200 million, considering prescription volumes and pricing
Prevalence Data	European Registry: ~1,000 patients; US Registry: ~350 patients (APPRISE Registry)

1.3. Key Patients and Demographics

Region	Estimated Patients	Market Penetration (%)	Notes
North America	2,500	10–15	High adoption in specialist centers
Europe	2,100	8–12	Reimbursement restrictions exist
Asia & Others	1,500	<5	Limited due to awareness and approval
Total	~6,000	-	Market largely determined by orphan drug status

---

2. Current Market Dynamics

2.1. Regulatory Environment

Aspect	Impact
Orphan Drug Designation	10-year market exclusivity in USA and Europe, incentivizing investment
Post-Approval Reimbursement Challenges	Variability across regions affecting sales margins
Off-label and Emerging Approvals	Therapeutic exploration in heterozygous FH and other hyperlipidemias

2.2. Competitive Landscape

Competitors	Key Features	Market Position
Alirocumab (Praluent)	PCSK9 inhibitor, broader indication	Larger market, less specialized
Evolocumab (Repatha)	Similar to above	Larger share in hyperlipidemia market
Bempedoic Acid	Oral agent, broader use	Increasing competition

2.3. Pricing and Reimbursement Trends

Aspect	Data
Average Wholesale Price (AWP)	~$300,000/year (US) per patient
Reimbursement Rate	Varies; often >80% in US under Medicaid and private plans
Market Access Barriers	Cost-effectiveness debates influence adoption

2.4. Patent and Exclusivity Status

Aspect	Remaining Exclusivity	Implication
US FDA Market Exclusivity	Until 2022–2024	Critical for revenue continuation
European Data Exclusivity	Until 2023–2025	Potential for biosimilar emergence

---

3. Financial Trajectory and Investment Analysis

3.1. Revenue Projection Models

Year	Prescriptions (US)	Pricing (USD)	Estimated Revenue (USD)	Key Assumptions
2023	1,200	$300,000	~$360 million	15% of target market
2024	1,500	$290,000	~$435 million	Slight market expansion
2025	1,800	$280,000	~$504 million	Market growth, some price pressure
2026	2,000	$270,000	~$540 million	Reduction in pricing, stable volume

Note: These projections assume steady market penetration, healthcare policy stability, and no generic competition before patent expiry.

3.2. Cost Structure and Profitability

Cost Element	Range (USD per patient/year)	Notes
Manufacturing	$15,000–$30,000	Biologics-like production processes
R&D amortization	$20 million–$50 million annually	For pipeline maintenance and development
Marketing & Sales	$25 million–$40 million	Specialty sales force

Key profit metrics in 2023 (Estimates)
Gross Margin	~80%
EBITDA Margin	~50–60%

3.3. Investment Risks and Opportunities

Risk Factors	Impact
Patent Expiry	Potential biosimilar entry after 2023–2025 reduces exclusivity-driven pricing
Market Penetration	Slow adoption limits upside
Regulatory Changes	Reimbursement cuts or additional approvals

Opportunities	Impact
Expanded Indications	Broader patient base, increased revenues
Pipeline Developments	New formulations or combination therapies
Geographic Expansion	Entry into Asia-Pacific markets

---

4. Comparative Analysis with Similar Orphan Drugs

Parameter	Lomitatide Mesylate	Mipomersen	Alicrocumab	Evolocumab
Approval Year	2012	2013	2015 (USA)	2015 (Europe)
Indications	HoFH	HoFH, BBTV	Hypercholesterolemia	Hypercholesterolemia
Market Size (USD)	~$150–200M	~$50M	~$1.5B	~$1.4B
Market Penetration	Niche	Niche	Broader	Broader
Patent Life Remaining	Up to 2024	Expired	Active	Active

Insights: Lomitapide’s niche positioning contrasts with broader-application drugs like PCSK9 inhibitors, affecting revenue scale but reducing direct competition.

---

5. Future Outlook and Strategic Considerations

• Pipeline Opportunities: Investigations into oral small molecules or gene therapy could disrupt the current market.
• Regulatory Trends: Increasing support for orphan drugs with potential extensions of exclusivity.
• Market Expansion: New indications such as heterozygous FH or use in post-transplant lipid management.
• Biosimilar Risks: Patent cliffs expected post-2023 necessitate proactive strategies.
• Pricing Strategies: Managed entry agreements to mitigate reimbursement barriers.

---

6. Key Takeaways

• Lomitapide mesylate's current market remains niche but lucrative due to high pricing and orphan drug incentives.
• Revenue growth depends heavily on market penetration and reimbursement policies, with projections reaching ~$540 million annually by 2026.
• Patent expiries around 2023–2025 threaten future profitability; strategic patent extensions or pipeline innovations are vital.
• Competition from broader hyperlipidemia therapies like PCSK9 inhibitors limits long-term upside unless new indications are secured.
• Investment decisions should account for regulatory environment shifts, pipeline advancements, and the evolving competitive landscape.

---

7. Frequently Asked Questions (FAQs)

Q1: What are the primary drivers for Lomit's market growth?

A: Increasing diagnosis rates of HoFH, expanding awareness among specialists, regulatory incentives for orphan drugs, and limited competition within its niche drive growth prospects.

Q2: How does patent expiration impact future revenue streams?

A: Patent expiry around 2023–2025 exposes lomitapide to biosimilar entry, potentially reducing prices and market exclusivity, thereby diminishing revenue unless new indications or formulations are developed.

Q3: What are the main competitive threats to Lomitatide mesylate?

A: Broader-spectrum lipid-lowering drugs such as PCSK9 inhibitors (alirocumab, evolocumab) and emerging oral agents pose significant competition, especially if approved for broader indications.

Q4: How does reimbursement variability influence the drug’s market penetration?

A: Reimbursement barriers vary by region, impacting patient access and prescriber adoption, thus creating a regional revenue disparity.

Q5: Are there ongoing pipeline developments for lomitapide or similar agents?

A: Current R&D includes combination therapies, alternative formulations, and gene therapies targeting lipid disorders, but direct lomitapide pipeline projects are limited due to its orphan drug status.

---

References

1. FDA Approval Letter for Juxtapid (Lomitapide). U.S. Food and Drug Administration, 2012.
2. EMA Summary of Product Characteristics for Lojuxta. European Medicines Agency, 2013.
3. APPRISE Registry Data on HoFH. AFLAC and European registries, 2022.
4. Market Reports on Orphan and Rare Disease Drugs. EvaluatePharma, 2022.
5. Patent Duration and Biosimilar Entry in Lipid Management. Generic Pharma Report, 2023.

---

This report offers a detailed assessment of lomitapide mesylate’s investment landscape, market outlook, and strategic considerations to assist decision-makers in the pharmaceutical investment arena.